HER2-pozitív emlötumorok célzott terápiá jában alkalmazott szerek és a terápiás válasz elörejelzése

Translated title of the contribution: HER2-positive breast cancer: Available targeted agents and biomarkers of therapy response

Mihály Zsuzsanna, B. Györffy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the last decade, the targeted therapy of breast cancer became part of routine clinical protocols all over the globe. Options in today's targeted therapy include hormonal therapy and the modulation of the EGFR/HER-pathway. Of the four HER receptors, HER2 is the target of currently used treatment strategies. HER2 activates multiple intracellular pathways via RAS, RAF and PI3K. We give a comprehensive summary of approved monoclonal antibodies and tyrosine kinase inhibitors acting over HER2, including trastuzumab, lapatinib and pertuzumab. We elaborate on their mechanism of action and on clinical trials behind their approval. Agents in third phase clinical studies (neratinib, afatinib) are also described. We give a brief overview of agents currently in phase I and phase II studies; these are acting over the PI3K pathway, over IGFR1 and over HSP90. Furthermore, currently validated negative biomarkers (markers predicting lack of response) in clinical use are also summarized. Finally, the major bottlenecks of clinical application including tumor heterogeneity and the high diversity of clinical studies are discussed. For a breakthrough we will need to identify new positive biomarkers of therapy response.

Original languageHungarian
Pages (from-to)147-156
Number of pages10
JournalMagyar Onkologia
Volume57
Issue number3
Publication statusPublished - 2013

Fingerprint

Biomarkers
Breast Neoplasms
Phosphatidylinositol 3-Kinases
Therapeutics
Clinical Protocols
Protein-Tyrosine Kinases
Monoclonal Antibodies
Clinical Trials
Neoplasms
Clinical Studies

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

HER2-pozitív emlötumorok célzott terápiá jában alkalmazott szerek és a terápiás válasz elörejelzése. / Zsuzsanna, Mihály; Györffy, B.

In: Magyar Onkologia, Vol. 57, No. 3, 2013, p. 147-156.

Research output: Contribution to journalArticle

@article{3197e6cc051d4a119b610743edfa4a67,
title = "HER2-pozit{\'i}v eml{\"o}tumorok c{\'e}lzott ter{\'a}pi{\'a} j{\'a}ban alkalmazott szerek {\'e}s a ter{\'a}pi{\'a}s v{\'a}lasz el{\"o}rejelz{\'e}se",
abstract = "In the last decade, the targeted therapy of breast cancer became part of routine clinical protocols all over the globe. Options in today's targeted therapy include hormonal therapy and the modulation of the EGFR/HER-pathway. Of the four HER receptors, HER2 is the target of currently used treatment strategies. HER2 activates multiple intracellular pathways via RAS, RAF and PI3K. We give a comprehensive summary of approved monoclonal antibodies and tyrosine kinase inhibitors acting over HER2, including trastuzumab, lapatinib and pertuzumab. We elaborate on their mechanism of action and on clinical trials behind their approval. Agents in third phase clinical studies (neratinib, afatinib) are also described. We give a brief overview of agents currently in phase I and phase II studies; these are acting over the PI3K pathway, over IGFR1 and over HSP90. Furthermore, currently validated negative biomarkers (markers predicting lack of response) in clinical use are also summarized. Finally, the major bottlenecks of clinical application including tumor heterogeneity and the high diversity of clinical studies are discussed. For a breakthrough we will need to identify new positive biomarkers of therapy response.",
keywords = "Biomarker, Breast cancer, ERBB2, Targeted therapy, Trastuzumab",
author = "Mih{\'a}ly Zsuzsanna and B. Gy{\"o}rffy",
year = "2013",
language = "Hungarian",
volume = "57",
pages = "147--156",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - HER2-pozitív emlötumorok célzott terápiá jában alkalmazott szerek és a terápiás válasz elörejelzése

AU - Zsuzsanna, Mihály

AU - Györffy, B.

PY - 2013

Y1 - 2013

N2 - In the last decade, the targeted therapy of breast cancer became part of routine clinical protocols all over the globe. Options in today's targeted therapy include hormonal therapy and the modulation of the EGFR/HER-pathway. Of the four HER receptors, HER2 is the target of currently used treatment strategies. HER2 activates multiple intracellular pathways via RAS, RAF and PI3K. We give a comprehensive summary of approved monoclonal antibodies and tyrosine kinase inhibitors acting over HER2, including trastuzumab, lapatinib and pertuzumab. We elaborate on their mechanism of action and on clinical trials behind their approval. Agents in third phase clinical studies (neratinib, afatinib) are also described. We give a brief overview of agents currently in phase I and phase II studies; these are acting over the PI3K pathway, over IGFR1 and over HSP90. Furthermore, currently validated negative biomarkers (markers predicting lack of response) in clinical use are also summarized. Finally, the major bottlenecks of clinical application including tumor heterogeneity and the high diversity of clinical studies are discussed. For a breakthrough we will need to identify new positive biomarkers of therapy response.

AB - In the last decade, the targeted therapy of breast cancer became part of routine clinical protocols all over the globe. Options in today's targeted therapy include hormonal therapy and the modulation of the EGFR/HER-pathway. Of the four HER receptors, HER2 is the target of currently used treatment strategies. HER2 activates multiple intracellular pathways via RAS, RAF and PI3K. We give a comprehensive summary of approved monoclonal antibodies and tyrosine kinase inhibitors acting over HER2, including trastuzumab, lapatinib and pertuzumab. We elaborate on their mechanism of action and on clinical trials behind their approval. Agents in third phase clinical studies (neratinib, afatinib) are also described. We give a brief overview of agents currently in phase I and phase II studies; these are acting over the PI3K pathway, over IGFR1 and over HSP90. Furthermore, currently validated negative biomarkers (markers predicting lack of response) in clinical use are also summarized. Finally, the major bottlenecks of clinical application including tumor heterogeneity and the high diversity of clinical studies are discussed. For a breakthrough we will need to identify new positive biomarkers of therapy response.

KW - Biomarker

KW - Breast cancer

KW - ERBB2

KW - Targeted therapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84891956410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891956410&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 147

EP - 156

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 3

ER -